Shah and colleagues highlighted that for relapsed/refractory patients with ALL who had prior treatment with CART19 cell therapy, utilizing CAR T-cells that targeted CD22 led to a 70% CR rate (73). This evidence concerns the gene CD22 and acute lymphoblastic leukemia.